Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is it coincidence to have the presentation schedule on 05/23 and 05/30 in a row?
Super news is coming here
I expect to see humongous P1 interim result of cancer tumor treatment
This small company is showing super positive result of Cancer treatment and Alzheimer
Why is Market cap under $25mil?
I think super explosion coming next week
online publication at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.
ePublication Details:
Title: Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion
Massive run start next week
Interim result of P1 cancer tumor trial is due this month
This news imply huge thing on the way
CEO is not traveling to China only to present the information
He has meeting with big Chinese pharma to make a huge deal
SANTA ANA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights of the Company’s cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01, which has demonstrated enhanced cytotoxicity and activating receptor expression for the treatment of neurodegenerative diseases and solid tumors, at the 5th International Cell & Gene Therapy China Summit & Exhibition (CGCS) to be held in Nanjing, China, from May 22–24, 2024.
CGCS will showcase exclusive new data in the several areas, including solid tumor treatment, off-the-shelf therapy, innovative cell therapy, AAV gene therapy, affordability of CGT, global cooperation, RNA therapeutics, and CGT commercialization. CGCS 2024 anticipates over 6,000 global attendees, more than 200 exhibitors, greater than 200 world-class speakers from large pharma, innovative biotech, and academia.
NKGen Presentation Details:
Title: Autologous NK Cell Therapy
Session: A: Cell Therapy Focus
Section: A2: Original Innovation in Cell Therapy – Universal and Solid Tumor Treatment
Date and Time: May 23, 2024, at 4:30 PM CST (China Standard Time) UTC/GMT +8
Dr. Song’s presentation will cover a variety of important topics, including industry challenges in manufacturing autologous NK cells at scale, which has been successfully overcome by NKGen’s next-gen CMC manufacturing process in its production of its autologous NK cell therapy product, SNK01. In addition, Dr. Song will discuss the results from SNK01 treatment in combination with either immune checkpoint inhibitors in patients with advanced solid tumors, or, in combination with Erbitux in tyrosine kinase inhibitor-resistant non-small cell lung cancer.
The presentation will also include the scientific rationale and supporting data behind the use of SNK01 in neurodegenerative disease specifically emphasizing the ability of SNK01 to improve levels of amyloid beta, tau, and alpha-synuclein proteins as well as GFAP, NfL, and YKL-40, which are elevated in numerous neurodegenerative diseases including Alzheimer’s, Parkinson’s, Lewy Body Dementia, Frontotemporal Dementia, Multisystem Atrophy, and Progressive Supranuclear Palsy alluding to the potential use of SNK01 to treat these diseases or as a possible prevention in high risk asymptomatic patients with elevated biomarkers.
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Mentioned: NKGN
GlobeNewswireApril 24, 2024
SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced an online publication at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31-June 4, 2024.
ePublication Details:
Title: Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion
Authors: Victoria Chua, Sant Chawla, Erlinda Gordon, William Feske, Lucia Hui, Hank Lee, Yoonmi Kang, Juan Mata, Katia Betito, Paul Chang, Paul Song
Be patient here
Huge P1 interim data for cancer tumor due this month and humongous P2 interim for moderate Alzheimer due next month
1000% explosion coming
MM's take it down on trading MM tot MM or short - buyers no interested on FDA 2e half 2024
Even with all the good news, traders showing not much interest here, volume too small??
NKGN has a TON of debt outstanding. Dilution for it has already started this morning. It's already killed the run.
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's Disease
Mentioned: NKGN
GlobeNewswireApril 29, 2024
NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson's disease.
The Company expects to initiate a Phase 1 clinical trial in PD in 2H 2024.
SANTA ANA, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug ("IND") application for SNK01 NK cell therapy for the treatment of Parkinson's disease ("PD"). SNK01 is an autologous, nongenetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, potentially addressing a novel approach to tackling Parkinson's disease.
The FDA IND clearance enables NKGen to initiate a Phase 1/2a clinical trial evaluating the safety, tolerability, and exploratory efficacy of SNK01 in patients with PD. The trial is designed to enroll up to 30 patients (20 receiving SNK01 and 10 receiving placebo). NKGen expects to begin the trial, with the first patient dosed, in the second half of 2024.
"The IND clearance marks a significant milestone as we advance our pipeline of NK cell therapy in neurodegenerative diseases," said Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen. "This is our second IND approval for SNK01 within the past several months and underscores our focused dedication towards developing safe and effective treatments that target both protein deposition and neuroinflammation for patients with neurodegenerative diseases such as Alzheimer's and Parkinson's. We are excited to start our first clinical trial in PD as there currently is a high unmet medical need in this indication."
Dr. Song further commented, "Given the encouraging outcomes regarding the reduction in neuroinflammation observed in our Phase 1 Alzheimer's trials, we are optimistic about the potential benefits that may emerge in our Parkinson's trial. Although these two neurodegenerative diseases differ, both share a neuroinflammatory component, which has led to our hypothesis that SNK01 may be beneficial in both indications. While directly inhibiting neuroinflammation, whether as an independent approach or in conjunction with other interventions, may not address the etiology, it can potentially decrease the production of factors that contribute to neurotoxicity, thereby hopefully leading to clinical improvements."
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
Mentioned: NKGN
GlobeNewswireApril 25, 2024
In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting immunoregulatory cytokines and identifying and eliminating autoreactive T cells that contribute to neuroinflammation.
SNK01 autologous NK cell therapy demonstrated a positive effect on improving cerebral spinal fluid ("CSF") and plasma levels of Tau, amyloid, and alpha-synuclein proteins in Alzheimer's patients suggesting a potential larger application in the treatment of other neurodegenerative diseases associated with these proteins.
90% of patients enrolled in the proof-of-concept Phase 1 Alzheimer's trial had improved or stable cognitive function at week 11 using the composite ADCOMS score.
SNK01 was also found to reduce neuroinflammation, showing improved levels of Glial Fibrillary Acid Protein (GFAP) in most patients, Neurofilament-light (NfL), Growth/Differentiation Factor-15 (GDF15), and Latent Transforming Growth Factor Beta Binding Protein 2 (LTBP2), suggesting a potential preventative clinical application for SNK01.
NKGen submitted an IND for SNK01 in Parkinson's disease ("PD") in Q1 2024 and anticipates to begin enrollment for its Phase 2 trial in advanced Alzheimer's disease ("AD") in Q2 2024.
SANTA ANA, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the details disclosed in today's presentation by Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, entitled "Evaluating Adoptive Cellular Immunotherapy for Neurodegeneration with Autologous SNK01", in which the Company shared additional information on the scientific rationale, preclinical and clinical data to date on the use of SNK01 enhanced NK cell therapy in patients with advanced AD and PD.
The presentation highlighted preclinical data showing the ability of SNK01 to phagocytose and digest both amyloid and alpha-synuclein proteins, the ability to secrete cytokines, which are able to inactivate inflammatory cells, as well as the ability to reduce autoreactive T cells, which have been implicated as a significant contributor to neuroinflammation and damage. In addition, compassionate use case studies of patients with advanced Alzheimer's disease and Parkinson's disease treated with SNK01 were presented as well as an update from the Company's Phase 1 Alzheimer's trial.
In the Phase 1 AD trial, SNK01 was administered intravenously ("IV") every three weeks for a total of four treatments using a 3+3 dose escalation design (1, 2, and 4 x 109 cells) in patients with either mild, moderate, or severe AD (Median MMSE of 14). Cognitive assessments and extensive CSF/plasma biomarker analyses were performed at baseline and at 1 and 12 weeks after the final dose. The primary endpoint was safety and secondary endpoints included changes in cognitive assessments and biomarker levels.
SNK01 was found to reduce and/or improve levels of pTau, amyloid AB42/40, and alpha-synuclein protein biomarkers suggesting that it could have utility far beyond Alzheimer's. 90% of patients enrolled in the proof-of-concept Phase 1 had improved or stable cognitive function at week 11 using the composite ADCOMS score.
In the presentation, Dr. Song commented, "While elevated amyloid AB42/40 is primarily implicated in Alzheimer's, alpha-synuclein protein levels have been noted in several other neurodegenerative diseases as well, including Parkinson's, Lewy Body Dementia, Multiple System Atrophy, and Pure Autonomic Failure. In addition, elevated Tau levels have been associated with Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration. We believe the ability of SNK01 to have a positive impact on all three proteins suggests that it could have clinical utility for numerous neurodegenerative diseases well beyond just Alzheimer's and Parkinson's. In addition, based on the recent publication by Guo, et al.1, which examined over 50,000 adults from the UK Biobank and found that GFAP, NfL, GDF15 and LTBP2 were consistently associated most with "incident all-cause dementia", biobank specimens from the Phase 1 trial were reassessed to explore the effect of SNK01 on each of these biomarkers."
Dr. Song further added, "In our dose escalation trial where the majority of the patients received suboptimal dosing and only four total treatments, we saw SNK01 was still able to reduce levels of all four biomarkers in at least 30% of all patients, suggesting that this could one day be potentially used as a safe preventative treatment for high-risk asymptomatic patients with elevated biomarkers especially with a higher dose. We are very impressed with the safety of SNK01 and ease of administration and its ability to cross the blood brain barrier. As more biomarker and clinical data emerge, we believe the potential applications of SNK01 will only increase."
Presentation Highlights:
SNK01 was shown to phagocytose and ingest amyloid and alpha-synuclein levels in vitro.
SNK01 was found to produce immunoregulatory cytokines in vitro.
SNK01 was found to reduce autoreactive T cells in vitro.
SNK01, given via a simple IV administration, appears to cross the blood brain barrier to improve AB42/40, Tau, and alpha-synuclein protein levels in CSF.
Despite a median MMSE score of 14, and 70% of patients treated at relatively low doses of SNK01, at one-week post-treatment (week 11):
50-70% of all enrolled patients in the trial had either stable or improved CDR-SB, ADAS-Cog and/or MMSE scores including one patient whose MMSE score improved from 14 to 23.
90% had either stable or improved ADCOMS scores.
60% of patients had improvements in GFAP and 30% of patients had improvements in NfL, GDF15, and LTBP2 after only four doses.
SNK01 appears safe and well tolerated, with no treatment-related adverse events observed; and the data suggest SNK01 may have potential clinical activity in AD. A larger Phase 2 placebo-controlled AD trial with a higher dosing and longer duration will begin to enroll in Q2 2024.
Rationale for use of SNK01 in Parkinson's was discussed along with the clinical trial plan to initiate a Phase 1 PD trial in 2H 2024.
A copy of the presentation is available on the Scientific Publications page of the Company's website at https://nkgenbiotech.com/.
1Guo Y et al. Plasma proteomic profiles predict future dementia in healthy adults. Nature Aging. 2024;4:247-260. https://doi.org/10.1038/s43587-023-00565-0.
Monster running higher
Trial result for Alzheimer and Pakinson and cancer tumor coming out
This is billion dollar stock
Great result for many trials keep on coming
CEO has planned systematic trial readout in a row
Another huge P2 interim result for Alzheimer is due in June as well
Pps will keep on going up to fair market valuation soon
Another catalyst in May
Huge interim result of P1 trial for cancer tumor
Huge news just out
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Mentioned: NKGN
GlobeNewswireApril 24, 2024
SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced an online publication at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31-June 4, 2024.
ePublication Details:
Title: Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion
Authors: Victoria Chua, Sant Chawla, Erlinda Gordon, William Feske, Lucia Hui, Hank Lee, Yoonmi Kang, Juan Mata, Katia Betito, Paul Chang, Paul Song
Abstract Number: e14515
Session Type: Publication Only
Session Title: Developmental Therapeutics - Immunotherapy
A copy of the ePublication will be available on the Scientific Publications page of the Company's website at https://nkgenbiotech.com/.
evry time down down
Going for $2 today and $3 tmrw and $5 on Thursday
So much undervalued
Super Volcano Explosion !!
Do not forget this was trading $3-$4 a month ago
Thus presentation is biggest annual meeting for Alzheimer and Pakinson
SAVA. Alzheimer stock trading at $880 mil mktcap now
What will happen here upon astounding data presentation of Alzheimer and Pakinson on Thursday
This Pps is a gift
1000% explosion coming this week
This is what happens when the float is locked up by big boys
This bio co is worth more than $200 mil with promising P1 result of Alzheimer
150 big pharmaceutical international companies will line up to make a deal after astounding data presentation this Thursday
Insiders holds majority shares here
8 mil float was locked up now
Shares Outstanding 5 22.81M
Implied Shares Outstanding 6 22.39M
Float 8.05M
% Held by Insiders 1 57.71%
% Held by Institutions 1 17.11%
AH or Tmrw for sure
Big boys are accumulating now
SANTA ANA, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that it has closed $5 million in second lien convertible loan funding with a term of 30 months, augmenting approximately $4.75 in gross cash proceeds from prior 2024 funding to date. Outstanding or issuable securities that may deliver additional cash to the company over time, or on large share and volume moves, after their pending issue and/or registration, include over two million forward purchase shares and our expectation of over ten million warrants with a cash strike price set, or expected to be reset, at $2.00 per share.
"This $5 million in funding is a statement of confidence and support for NKGen, our team, and our story in a challenging market. This provides breathing room for us to execute our plans, continue to pursue larger funding opportunities with both financial and strategic investors, and capitalize on our outstanding structured securities upon registration of the underlying shares. It will help fund our clinical trials and operations, filing of our annual report on Form 10-K, and filing of an amended registration statement on Form S-1 soon thereafter. This will help us to achieve additional value-creating milestones across both our neurodegenerative and oncology clinical programs and repay certain bridge funding liabilities," said Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech.
Dr. Song continued, "We are intently focused on our upcoming Phase 2 Alzheimer's clinical trial and recently submitted an IND for Parkinson's disease while streamlining our resources for maximum efficiency. Accordingly, we have successfully reduced our monthly burn rate for operations and clinical trials by almost 50%. In addition, we have several catalysts expected this year including data readouts (both safety and cognitive) for the Phase 1 portion of our moderate Alzheimer's trial and the initiation of Phase 2."
why do you not see an offering? no cash
Pps will keep going up as the low float being locked up
There is no offering risk here
My prediction Pps over $5 - $10 this week
This could explode over $10 this week
Only $250 mil mktcap at $10
Some group buying up the float before the data presentation
NKGN must be trading over $200 mil mktcap now
Just $30 mil mktcap now
I have no idea why the mktcap is at $25 mil right now
MM and shorts manipulation caused the pps suppression
I added huge at low Pps and will wait until P2 interim readout in June for 1000% profit
This Pps is a gift indeed
It is big thing to present at 12th annual Alzheimer and Parkinson’s summit so many big pharmaceutical companies attending
NJGN is presenting P1 complete results of Alzheimer and preclinical Pakinson data as well
This company is worth $1 billion mktcap
Good luck all
NKGN will be buyout candidate by many big pharmaceutical companies after the presentation at the summit next week
$5 billion - $10 billion buyout price
After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab’s clinically proven 30% reduction in cognitive decline receiving the green light from the FDA & PMDA and Eli Lilly’s Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development.
The 12th Alzheimer’s & Parkinson’s Drug Development Summit is indisputably the ultimate industry-focused meeting dedicated to sharing the hottest unpublished AD & PD research from senior biopharma KOLs you won’t hear anywhere else, with deep-dive content all the way from early discovery through to late phase trials and approvals.
This April, join 150+ senior industry leaders across discovery, preclinical, biomarker, translational, clinical, and commercial this year from Eli Lilly, Biogen, Eisai, Abbvie, Merck, Michael J. Fox Foundation, Acumen, Vigil Neuroscience, and many more….
Keep running in horrible red market
Something big news coming next week
So much undervalued at $25 mil mktcap
The fair value is $500 mil mktcap with P2 interim result coming in June and new indication of Pakinson as well
This could be $100 stock this year
Alzheimer P2 interim result due in June
1000% in 2 months
the market is well aware.
you have nothing science wise?
This was trading around $3-$4 a month ago
I think it will go higher upon Parkinson’s new data next week as well as Alzheimer’s
Billion dollars market
you are strawmanning all over the place.
Provide an argument please.
Im a bull too! Like CEOs optimism and improvement of cognitive. But the NKMax tie in is a stick in the soup.
1000% explosion coming sooner than I anticipated
Alzheimer and Parkinson’s market is more than $60 billion worldwide
Pls make the case on actual superiorerity via arguments. Claiming is easy.
NKGN is worth billion dollars based on P1 result of Alzheimer and preclinical result of Pakinson disease
Super explosion upon the data explosion next week
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
Mentioned: NKGN
GlobeNewswireApril 18, 2024
SANTA ANA, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details around its NK cell therapy in neurodegenerative disease, review its preclinical data in Parkinson's disease, and highlight clinical safety and efficacy data from the Company's recently completed Phase 1 clinical trial of SNK01, autologous natural killer cell therapy, in Alzheimer's disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit to be held in Boston, MA, from April 23-25, 2024.
Presentation Details:
Title: Evaluating Adoptive Cellular Immunotherapy for Neurodegeneration with Autologous SNK01
Conference Track: Translational -- Harnessing Cell Therapy & Senescence to Reduce Alzheimer's Pathology in Preclinical Research
Date and Time: Thursday, April 25, 2024, 2:00 pm ET
Dr. Song's presentation will detail how enhanced natural killer cells can maximize the body's ability to destroy diseased and abnormal cells and provide a review of NK cell therapy as an alternative treatment modality to resolve neurodegeneration by harnessing the body's natural immune system, including a discussion on the scientific rationale behind the use of NK cell therapy for the treatment of Parkinson's disease. Dr. Song will also present clinical safety and efficacy data from the Company's recently completed Phase 1 clinical trial evaluating autologous SNK01 NK cell therapy in patients with Alzheimer's disease (NCT04678453).
A copy of the presentation will be available on the Scientific Publications page of the Company's website at https://nkgenbiotech.com/ once the presentation has concluded. Previously disclosed Phase 1 data on the positive effects of SNK01 on amyloid, tau and neuroinflammation biomarkers, which may not be included in this conference presentation, can also be found on the Scientific Publications page.
You are dead wrong
NKGN became associate company now and IPO thru spac merger last year
Nothing to do with NK Max in Korea
Followers
|
9
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
153
|
Created
|
10/27/23
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |